BHVN NYSE
Biohaven Ltd.
1W: -11.2%
1M: -13.0%
3M: +43.6%
YTD: +27.0%
1Y: +2.0%
3Y: -45.9%
$13.77
-0.74 (-5.13%)
Weekly Expected Move ±9.8%
$12
$13
$14
$16
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range7.48-18.566
Volume3,249,702
Avg Volume2,899,026
Beta3.14
Dividend—
Analyst Ratings
Company Info
CEOVladimir Coric
Employees274
SectorHealthcare
IndustryBiotechnology
IPO Date2022-09-23
Websitebiohaven.com
215 Church Street
New Haven, CT 06510
US
New Haven, CT 06510
US
203 404 0410
About Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Latest News
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of “Moderate Buy” from Analysts
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Insider Monkey
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials
5 Stocks Paying Off Big Time - Insider Monkey
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares - simplywall.st
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Volles Warren Karl | 0 | — | 2026-07-09 | |
| Volles Warren Karl | 300,000 | $7.00 | 2026-07-09 | |
| Volles Warren Karl | 78,750 | $29.49 | 2026-07-09 | |
| Volles Warren Karl | 95,250 | $41.93 | 2026-07-09 | |
| Volles Warren Karl | 83,000 | $38.64 | 2026-07-09 |